What does OrganOx do?
OrganOx is a commercial stage organ technology company that develops advanced solutions for patients with acute or chronic organ failure. Their flagship product, the OrganOx metra, is a normothermic machine perfusion platform designed to maintain donor organs in active condition outside the body.
How much did they raise?
The company raised $160M in primary and secondary equity financing. Lead investors include Intuitive Ventures, Piper Heartland Healthcare, and Terumo Ventures, although the specific round type was not disclosed.
What are their plans for the money?
OrganOx intends to use the funds to expand its operations and further its development efforts, aiming to improve organ preservation techniques and transplant outcomes globally. This could significantly impact patient care by extending organ viability and enhancing the assessment process before transplantation.
What have they achieved so far?
The OrganOx metra platform has been approved in the U.S., Europe, Canada, and Australia and has already been used in over 5,000 liver transplants, demonstrating its effectiveness in keeping donor livers viable.
